American Journal of Epidemiology · 2002 · 79 citations · 27 references
Public HealthHealth SciencesOncologyCancer EpidemiologyEpidemiologic MethodsEpidemiologyAlcohol Use EpidemiologyCancer RiskDiet EpidemiologyPopulation-based Cancer ControlAge-related Drinking PatternsAlcohol Consumption PatternsAlcohol-related Cancer RiskConfidence Intervals For Odds RatiosLogistic RegressionPopulation Cancer RegistriesPopulation-based RegistriesRandom Digit Dialing
The relation between wine consumption and non-Hodgkin's lymphoma (NHL) was investigated using data from the Selected Cancers Study. Cases (n = 960) were men aged 32-60 years diagnosed with NHL from 1984 to 1988 and identified from eight US population-based cancer registries. Controls (n = 1,717) were men recruited by random digit dialing and frequency matched to cases by age and registry. Logistic regression was used to calculate odds ratios and 95% confidence intervals adjusted for age, registry, race/ethnicity, education, and smoking. Odds ratios for men who consumed less than one and those who consumed one or more wine drinks per day were 0.8 (95% confidence interval: 0.5, 1.3) and 0.4 (95% confidence interval: 0.2, 0.9) compared with nondrinkers, respectively (p for trend = 0.02). Among wine drinkers who consumed alcohol beverages from ages 16 years or less, odds ratios for intakes of less than one and one or more wine drinks per day were 0.4 (95% confidence interval: 0.2, 0.97) and 0.3 (95% confidence interval: 0.1, 0.8), respectively (p for trend = 0.004). No associations were evident for beer or spirits. These data show that consumption of wine, but not of beer or spirits, is associated with a reduced NHL risk.
27
Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes
Meishiang Jang, Lining Cai, George Udeani et al. · Science · 1997 · 4.9K citations
Medicine, Oncology, Pharmacology +17
Ahmedin Jemal, Anish Thomas, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2002 · 2.9K citations · Full text
Medicine, Demography, Oncology +17